Morgan Stanley Reiterates Equal-Weight on Ascendis Pharma, Maintains $109 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit has reiterated an Equal-Weight rating on Ascendis Pharma (NASDAQ:ASND) and maintained a price target of $109.
July 24, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Ascendis Pharma and maintained a price target of $109.
The news is directly about Ascendis Pharma and is likely to have a neutral impact on its stock price in the short term. The Equal-Weight rating suggests that the stock is expected to perform in line with the market or other stocks in its sector. The maintained price target indicates that the analyst's view on the company has not changed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100